LEVOXYL (nda021301)- (0.025MG,0.025MG,0.05MG,0.05MG,0.075MG,0.075MG,0.088MG,0.088MG,0.1MG,0.1MG,0.112MG,0.112MG,0.125MG,0.125MG,0.137MG,0.137MG,0.15MG,0.15MG,0.175MG,0.175MG,0.2MG,0.2MG,0.3MG)

Generic Name	LEVOTHYROXINE SODIUM	Innovator	KING PHARMS
Dosage	0.025MG,0.025MG,0.05MG,0.05MG,0.075MG,0.075MG,0.088MG,0.088MG,0.1MG,0.1MG,0.112MG,0.112MG,0.125MG,0.125MG,0.137MG,0.137MG,0.15MG,0.15MG,0.175MG,0.175MG,0.2MG,0.2MG,0.3MG
ParaIV Filing	Yes	505(b)2 Filing	Yes
Last Patent Expiry	2023-Oct-02	NCE Excl Expiry	Expired
ODE Expiry	None	NP Expiry	None
GAIN Expiry	None	Drug Complexity	No
Indication	LEVOXYL is L-thyroxine (T4) indicated in pediatric and adult patients for:  Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.  Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer.

Approvals and Launches

Final Approvals	Tentative Approvals	Generic Launches
0	0	0

Other Developers

Total Other Developers	19

Drugs with Suitability

Drugs with Suitability	No

Drug Pricing

	NDA			ANDA
Dosage	Weekly	Monthly	Yearly	Yearly Up	Yearly Down
0.025MG	**	**	Up	-	-
0.05MG	**	**	Up	-	-
0.075MG	**	**	Up	-	-
0.088MG	**	**	Up	-	-
0.1MG	**	**	Up	-	-
0.112MG	**	**	Up	-	-
0.125MG	**	**	Up	-	-
0.137MG	**	**	Up	-	-
0.15MG	**	**	Up	-	-
0.175MG	**	**	Up	-	-
0.2MG	**	**	Up	-	-
0.3MG	**	**	-	-	-

Drug Sales

NDA Sales Available	Total Generic Sales Available
Yes	0

Manufacturing Details of LEVOXYL